Humoral and cellular cmv responses in healthy donors; identification of a frequent population of CMV-specific, CD4+ T cells in seronegative donors

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Loeth, Nina ^a   Assing, Kristian ^b   Madsen, Hans O ^b   Vindeløv, Lars ^b   Buus, Soren ^a   Stryhn, Anette ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; MATRIX PROTEIN; PHOSPHOPROTEIN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD DONOR; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ASSAY; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOMEGALOVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IN VITRO STUDY; NONHUMAN; SERODIAGNOSIS; VIRUS DETECTION; CYTOMEGALOVIRUS INFECTION; DONOR; IMMUNOLOGY; VIROLOGY;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; PHOSPHOPROTEINS; TISSUE DONORS; VIRAL MATRIX PROTEINS;

EID: 84856702229     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031420     Document Type: Article

References (45)

1. Ho M, (1990) Epidemiology of cytomegalovirus infections. Rev Infect Dis 12 (Suppl 7): S701-710.
2. Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, et al. (2006) Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 43: 1143-1151.
3. Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, et al. (2003) Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101: 407-414.
4. Boeckh M, Nichols WG, (2004) The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 103: 2003-2008.
5. Emanuel D, Cunningham I, Jules-Elysee K, Brochstein JA, Kernan NA, et al. (1988) Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 109: 777-782.
6. Emery VC, (2001) Investigation of CMV disease in immunocompromised patients. J Clin Pathol 54: 84-88.
7. Zhou W, Longmate J, Lacey SF, Palmer JM, Gallez-Hawkins G, et al. (2009) Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood 113: 6465-6476.
8. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, et al. (2003) Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 102: 4255-4260.
9. Ljungman P, Perez-Bercoff L, Jonsson J, Avetisyan G, Sparrelid E, et al. (2006) Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 91: 78-83.
10. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, et al. (2003) Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant 9: 543-558.
11. Ljungman P, (2007) Risk assessment in haematopoietic stem cell transplantation: viral status. Best Pract Res Clin Haematol 20: 209-217.
12. Kern F, Bunde T, Faulhaber N, Kiecker F, Khatamzas E, et al. (2002) Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis 185: 1709-1716.
13. Slezak SL, Bettinotti M, Selleri S, Adams S, Marincola FM, et al. (2007) CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects. J Transl Med 5: 17.
14. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, et al. (2005) Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 202: 673-685.
15. Waldrop SL, Pitcher CJ, Peterson DM, Maino VC, Picker LJ, (1997) Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest 99: 1739-1750.
16. Almyroudis NG, Jakubowski A, Jaffe D, Sepkowitz K, Pamer E, et al. (2007) Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 9: 286-294.
17. Broers AE, van Der Holt R, van Esser JW, Gratama JW, Henzen-Logmans S, et al. (2000) Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 95: 2240-2245.
18. Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, et al. (2005) Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 202: 379-386.
19. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, et al. (2002) Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99: 3916-3922.
20. Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, et al. (2003) Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 362: 1375-1377.
21. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, et al. (1992) Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257: 238-241.
22. Kern F, Faulhaber N, Frommel C, Khatamzas E, Prosch S, et al. (2000) Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol 30: 1676-1682.
23. Maecker HT, Dunn HS, Suni MA, Khatamzas E, Pitcher CJ, et al. (2001) Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods 255: 27-40.
24. Gandhi MK, Khanna R, (2004) Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 4: 725-738.
25. Sester M, Gartner BC, Sester U, Girndt M, Mueller-Lantzsch N, et al. (2003) Is the cytomegalovirus serologic status always accurate? A comparative analysis of humoral and cellular immunity. Transplantation 76: 1229-1230.
26. La Rosa C, Limaye AP, Krishnan A, Longmate J, Diamond DJ, (2007) Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis 195: 633-644.
27. Sinclair E, Black D, Epling CL, Carvidi A, Josefowicz SZ, et al. (2004) CMV antigen-specific CD4+ and CD8+ T cell IFNgamma expression and proliferation responses in healthy CMV-seropositive individuals. Viral Immunol 17: 445-454.
28. Vafai A, Wroblewska Z, Graf L, (1990) Antigenic cross-reaction between a varicella-zoster virus nucleocapsid protein encoded by gene 40 and a herpes simplex virus nucleocapsid protein. Virus Res 15: 163-174.
29. Kitamura K, Namazue J, Campo-Vera H, Ogino T, Yamanishi K, (1986) Induction of neutralizing antibody against varicella-zoster virus (VZV) by VZV gp3 and cross-reactivity between VZV gp3 and herpes simplex viruses gB. Virology 149: 74-82.
30. Edson CM, Hosler BA, Respess RA, Waters DJ, Thorley-Lawson DA, (1985) Cross-reactivity between herpes simplex virus glycoprotein B and a 63,000-dalton varicella-zoster virus envelope glycoprotein. J Virol 56: 333-336.
31. Damle RG, Yeolekar LR, Rao BL, (1998) Strain analysis and epitope mapping of West Nile virus using monoclonal antibodies. Acta Virol 42: 389-395.
32. Kimura-Kuroda J, Yasui K, (1986) Antigenic comparison of envelope protein E between Japanese encephalitis virus and some other flaviviruses using monoclonal antibodies. J Gen Virol 67 (Pt 12): 2663-2672.
33. Fonteneau JF, Larsson M, Somersan S, Sanders C, Munz C, et al. (2001) Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells. J Immunol Methods 258: 111-126.
34. Oelke M, Moehrle U, Chen JL, Behringer D, Cerundolo V, et al. (2000) Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy. Clin Cancer Res 6: 1997-2005.
35. Tsai V, Kawashima I, Keogh E, Daly K, Sette A, et al. (1998) In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells. Crit Rev Immunol 18: 65-75.
36. Ocadlikova D, Kryukov F, Mollova K, Kovarova L, Buresdova I, et al. (2010) Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT- drived nonapeptides or myeloma cell apoptotic bodies. Neoplasma 57: 455-464.
37. Lutz MB, Schuler G, (2002) Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 23: 445-449.
38. Bonasio R, von Andrian UH, (2006) Generation, migration and function of circulating dendritic cells. Curr Opin Immunol 18: 503-511.
39. Boscardin SB, Hafalla JC, Masilamani RF, Kamphorst AO, Zebroski HA, et al. (2006) Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med 203: 599-606.
40. Moser JM, Sassano ER, Leistritz del C, Eatrides JM, Phogat S, et al. (2010) Optimization of a dendritic cell-based assay for the in vitro priming of naive human CD4+ T cells. J Immunol Methods 353: 8-19.
41. Gamadia LE, Rentenaar RJ, van Lier RA, ten Berge IJ, (2004) Properties of CD4(+) T cells in human cytomegalovirus infection. Hum Immunol 65: 486-492.
42. Krause H, Hebart H, Jahn G, Muller CA, Einsele H, (1997) Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant 19: 1111-1116.
43. Sester M, Sester U, Gartner B, Heine G, Girndt M, et al. (2001) Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 71: 1287-1294.
44. Widmann T, Sester U, Gartner BC, Schubert J, Pfreundschuh M, et al. (2008) Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation. PLoS ONE 3: e3634.
45. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, et al. (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333: 1038-1044.